

Lexaria Bioscience Corp.

16:17 17 Sep 2019

Lexaria Bioscience's DehydraTECH technology earns spot in medical journal with promising human CBD study results

Lexaria Bioscience Corp (CSE:LXX) (OTCQX:LXRP) said a study evaluating CBD delivery using its DehydraTECH technology has been published in the medical journal *Advances in Therapy*.

The 2018 study found that a 90 milligram dose of TurboCBD — made using DehydraTECH — resulted in significantly higher levels of CBD levels in the subjects' plasma after 90 and 120 minutes than a generic CBD dose.

Only TurboCBD performed better than a placebo after 30 minutes and continued to do so after four hours.

READ: Lexaria Bioscience picks up new patent for DehydraTECH drug delivery technology

Additionally, mean arterial blood pressure was significantly decreased only with the TurboCBD compared to baseline measures. Cerebral perfusion, a measure of blood to the brain, was shown to increase relative to baselines only with TurboCBD.

Increasing blood to the brain is particularly notable, the company said, since last month it was granted two patents that cover DehydraTech for the treatment of conditions including "neurological diseases such as Alzheimer's, Parkinson's, schizophrenia."

The study was conducted in a dozen young male athletes, and researchers concluded that more studies are warranted.

"Further acute and chronic dosing investigations in older and cerebrovascular-compromised patients may shed light on the vascular and clinical impacts of increased CBD bioavailability," investigators said in the article.

The journal article also referenced a separate study involving a competitor, Lexaria said, which evaluated a similar CBD dose with bioabsorption. The 90mg TurboCBD dose achieved a higher maximum plasma concentration and outperformed the competitor's 100mg dose up until about 3.5 hours after administration.

The *Advanced Therapy* article, published September 12, is titled, "Examination of a New Delivery Approach for Oral Cannabidiol in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Pharmacokinetics Study."

Lexaria's share price increased 5.6% to C\$0.94 on the CSE on Tuesday and 4.1% to US\$0.71 on OTC Markets.


—Updated to include stock movement—

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Price: 0.63

Market Cap: \$50.85 m

1 Year Share Price Graph



February 2019 August 2019 February 2020

Share Information

Code: LXX

Listing: CSE

52 week	High	Low
	1.95	0.4

Sector: Cannabis

Website: www.lexariabioscience.com

Company Synopsis:

Lexaria Bioscience Corp has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Many vitamins, drugs, supplements and other beneficial molecules are lipophilic (i. e.

action@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).